Survey
Quarterly Survey: Diffuse large B-cell lymphoma (DLBCL) and Polivy January 2024
Ticker(s): RHHBYThis survey includes 20 Hematologist.
How many patients with diffuse large B-cell lymphoma (DLBCL) do you have under your care?
How would you best describe your practice?
- Academic
- Community
- Private
- Other
How many of your patients with DLBCL started Polivy (polatuzumab vedotin-piiq) in the past 30 days?
How many of your patients with DLBCL discontinued Polivy (polatuzumab vedotin-piiq) in the past 30 days?
How many of your patients with DLBCL do you expect to start Polivy (polatuzumab vedotin-piiq) in the next 30 days?
How would you rate Polivy (polatuzumab vedotin-piiq) on the following (where 1 is low and 5 is high)?
- Safety
- Efficacy
- Patient access
- Patient willingness to try
In your opinion, how effective is Polivy (polatuzumab vedotin-piiq) in treating DLBCL compared to other treatments? Please be specific.
What line of treatment would you consider Polivy (polatuzumab vedotin-piiq) for patients with DLBCL?
How does/will cost specifically impact access to Polivy (polatuzumab vedotin-piiq) for patients with DLBCL?
- No impact:
- Minor impact:
- Moderate impact:
- Significant impact:
- I am not sure:
Do you plan to increase your use of Polivy (polatuzumab vedotin-piiq) ?
- Yes
- No
- Not Sure
Why or why not? Please elaborate on your response above.
Please elaborate on your view of Polivy (polatuzumab vedotin-piiq). Please be specific.
What are your thoughts on the recent data from the POLARIX study regarding Polivy's efficacy as a first-line treatment for DLBCL?
How do you perceive the potential impact of Polivy as a first-line treatment for DLBCL compared to its current use as a third-line treatment?
Are there any challenges or considerations associated with using Polivy in the first-line setting that you foresee?
On a scale of 1-10 (where 1 is low and 10 is high) how excited are you for Polivy (polatuzumab vedotin-piiq) in treating DLBCL?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
